Quest Diagnostics Adds Alzheimer's Test After CEO Exit
Quest Diagnostics is adding Roche's FDA-cleared Alzheimer's blood test to its menu as the stock trades 25% above the price where the CEO sold shares seven weeks ago. The Q2 2026 EPS beat of 10.6% was
Quest Diagnostics Plans Alzheimer's Test After CEO Exit
NEW YORK, August 24 —
Quest Diagnostics Incorporated (DGX) is adding Roche's newly FDA-cleared Alzheimer's blood test to its menu, a move that comes with the stock trading 25% above where the CEO sold his shares, seven weeks before the company's biggest quarterly earnings beat in four periods.
- Q2 2026 EPS of $3.12 beat the $2.82 consensus by 10.6%, the biggest of four consecutive quarterly beats.
- CEO J.E. Davis sold 10,000 shares at $194.14 on June 1; SVP Kuppusamy sold 8,147 at $200.00 on June 4.
- Trailing revenue of $11.56 billion, up 10.2%; $6.40 billion debt against $0.63 billion cash; stock at $243.87.
The Exit Looks Different From Here
CEO J.E. Davis sold 10,000 DGX shares at $194.14 on June 1, 2026, collecting $1.94 million. Three days later, SVP Karthik Kuppusamy (Clinical Solutions) sold 8,147 shares at $200.00 after exercising options at $121.81 and $127.72, pocketing another $1.63 million. Seven weeks later, Quest filed its Q2 2026 8-K and the stock sits at $243.87-25% above the CEO's exit price. Insiders may have had legitimate diversification reasons; but with the Chief Commercial Officer selling 1,600 shares five days post-earnings at $235.18, the pattern across three executives is hard to dismiss. Aggregate insider buying over the trailing 90 days: $0.
Four Quarters That Earned a Premium
Quest Diagnostics operates under five brands, Quest Diagnostics, AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum, serving hospitals, physicians, health plans, and employers with tests spanning cancer pathology, cardiometabolic panels, prenatal genetics, and workplace drug screening of urine, hair, and oral fluid. The company has beaten EPS consensus in each of the last four quarters, with the margin widening from 4.0% in Q3 2025 to its widest in four periods last quarter. Trailing revenue grew 10.2% to $11.56 billion and operating cash flow of $1.9 billion supports a 33.2% gross margin across a workforce of approximately 46,000.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| DGX | $26.9B | 20.2x | +36.8% |
| LH | $27.5B | 17.1x | +21.8% |
| DVA | $11.3B | 10.4x | +26.6% |
| BDX | $52.0B | 14.3x | +25.5% |
| UHS | $10.4B | 7.3x | -3.6% |
| CAH | $54.0B | 16.5x | +57.2% |
The Alzheimer's Test Changes the Math, But Not the Ceiling
The Roche Alzheimer's blood test extends a diagnostic menu that already covers neurology, prenatal genetics, cancer, and infectious disease: a logical addition, not a strategic shift. The real constraint is the balance sheet: $6.40 billion in debt against $0.63 billion cash, or $5.77 billion in net leverage. DGX trades near the $245.87 consensus analyst price target; at 20.2x forward earnings against $910 million in trailing free cash flow, investors can use a DCF calculator to pressure-test whether the multiple holds. Q3 EPS is the checkpoint: a fifth consecutive beat would mean insiders simply sold too soon. Run the free Quest Diagnostics Incorporated deep-dive →
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
What Alzheimer's test is Quest Diagnostics adding?
Quest Diagnostics is adding Roche's newly FDA-cleared Alzheimer's blood test to its menu. The company describes it as a logical extension of a diagnostic menu that already covers neurology alongside prenatal genetics, cancer, and infectious disease.
How much did Quest Diagnostics beat EPS estimates in Q2 2026?
Quest Diagnostics reported Q2 2026 EPS of $3.12 against a $2.82 consensus, a beat of 10.6%. This was the largest margin of outperformance across four consecutive quarters of EPS beats.
Why did the Quest Diagnostics CEO sell shares?
CEO J.E. Davis sold 10,000 shares at $194.14 on June 1, 2026, generating $1.94 million in proceeds. The company has offered no public explanation; insiders may have had legitimate diversification motives, but the directional pattern across three executives selling within weeks of each other is notable, with aggregate insider buying over the trailing 90 days at $0.
How much debt does Quest Diagnostics carry?
Quest Diagnostics carries $6.40 billion in debt against $0.63 billion in cash, resulting in $5.77 billion in net leverage. The article identifies this balance sheet as the binding constraint on the investment case, even as the Alzheimer's test adds a new growth avenue.
What is the analyst price target for Quest Diagnostics?
The consensus analyst price target stands at $245.87. With the stock at $243.87 at the time of publication, Quest Diagnostics is trading essentially at that target, leaving little room in the multiple for a miss on Q3 earnings.
Roche's Alzheimer's blood test has received FDA clearance and Quest Diagnostics has announced plans for a U.S. launch — adding a potential growth catalyst for the nation's largest independent diagnostics company. The announcement arrives as DGX trades at $243.87, well above the $194–$200 range where the CEO and a senior vice president sold millions in stock approximately seven weeks before Quest reported its largest quarterly earnings beat in more than a year.